Dr Sabine Steiner (Medical University of Vienna, Vienna, AT) discusses the 2-year results from the COMPARE trial.
The study compared low-dose (Ranger) vs. high-dose (Impact) DCB in femoropopliteal arteries.
Questions
1. What is the background of this study? What makes it unique?
2. Can you define the difference between low and high dosing in this study?
3. What was the design of the study and which patients were eligible?
4. What are the main outcomes presented at LINC 2021?
5. How should these findings be interpreted?
6. VA
Recorded remotely from Leipzig, 2021.
Editor: Mirjam Boros
Recording Editor: Natascha Wienand